A detailed history of Advantage Alpha Capital Partners LP transactions in Tg Therapeutics, Inc. stock. As of the latest transaction made, Advantage Alpha Capital Partners LP holds 22,379 shares of TGTX stock, worth $661,075. This represents 0.12% of its overall portfolio holdings.

Number of Shares
22,379
Previous 34,030 34.24%
Holding current value
$661,075
Previous $605,000 13.55%
% of portfolio
0.12%
Previous 0.14%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$17.21 - $25.28 $200,513 - $294,537
-11,651 Reduced 34.24%
22,379 $523,000
Q2 2024

Aug 13, 2024

BUY
$13.32 - $19.19 $453,279 - $653,035
34,030 New
34,030 $605,000

Others Institutions Holding TGTX

About TG THERAPEUTICS, INC.


  • Ticker TGTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 145,274,000
  • Market Cap $4.29B
  • Description
  • TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...
More about TGTX
Track This Portfolio

Track Advantage Alpha Capital Partners LP Portfolio

Follow Advantage Alpha Capital Partners LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Advantage Alpha Capital Partners LP, based on Form 13F filings with the SEC.

News

Stay updated on Advantage Alpha Capital Partners LP with notifications on news.